Key facts
- Syenex’s last known valuation is $22.0M (Jan 2025).
- It has raised $13.7M across 2 recorded rounds; the latest was Early Stage VC ($8.7M) in Jan 2025.
- Notable investors include MedTech Innovator, AlleyCorp, Lightbank (Venture Capital), Constellation Technology Ventures, KdT Ventures — 9 tracked in total.
- Syenex has filed 3 Form Ds with the SEC since 2022, most recently Jan 2025 ($8.7M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Syenex
Funding rounds
2 roundsAbout Syenex
Developer of bioengineering technologies designed to improve the precision and effectiveness of therapeutic cell engineering. The company offers optimized enveloped vector surface compositions, programmable payload-compatible delivery systems, scalable manufacturing integrations, and regulatory support services, enabling drug developers and biotechnology researchers to create advanced medicines with greater efficiency and reliability.
- Sector
- Healthcare
- HQ
- Evanston, IL, United States
- Founded
- 2022
- Employees
- 8
- Website
- syenex.com/
- Ownership
- Privately Held (backing)
Syenex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syenex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syenex in its N-PORT filings yet. We sweep new filings monthly.